Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Platelets are essential for clotting in the blood and maintenance of normal hemostasis. Under pathologic conditions such as atherosclerosis, vascular injury often results in hyperactive platelet activation, resulting in occlusive thrombus formation, myocardial infarction, and stroke. Recent work in the field has elucidated a number of platelet functions unique from that of maintaining hemostasis, including regulation of tumor growth and metastasis, inflammation, infection, and immune response. Traditional therapeutic targets for inhibiting platelet activation have primarily been limited to cyclooxygenase-1, integrin αIIbβ3, and the P2Y12 receptor. Recently identified signaling pathways regulating platelet function have made it possible to develop novel approaches for pharmacological intervention in the blood to limit platelet reactivity. In this review, we cover the newly discovered roles for platelets as well as their role in hemostasis and thrombosis. These new roles for platelets lend importance to the development of new therapies targeted to the platelet. Additionally, we highlight the promising receptor and enzymatic targets that may further decrease platelet activation and help to address the myriad of pathologic conditions now known to involve platelets without significant effects on hemostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 1×
“…models, by which they reduced venous thrombus formation, has supported the role of platelets in the pathophysiology of venous thrombosis (Herbert et al., 1993; Bernat and Herbert, 1994; Savi et al., 1994, 2000; Imbault et al., 1996; Arroyo et al., 2001; Moore and Deschler, 2007; Wang et al., 2007).”
BackgroundPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 2×
“Importantly, anti-PAR4 antibodies did not significantly prolong bleed times in the guinea pig cuticleand renal-provoked bleeding time models (Wong et al., 2017).”
BackgroundInfluentialKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood
Clark, S. R., Ma, A. C., Tavener, S. A., McDonald, B., Goodarzi, Z., Kelly, M. M., Patel, K. D., Chakrabarti, S., McAvoy, E., Sinclair, G. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1565 · Cited by 2,309
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086 · cited 4×
“The shift in integrin affinity or conformational change is facilitated by the binding of talin and kindlin, to the intracellular b3 domain (Shattil et al., 2010).”
BackgroundInfluentialAmsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases
Gasparyan, A. Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M., & Kitas, G. D. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.4.345 · Cited by 607
Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism
Brighton, T. A., Eikelboom, J. W., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210384 · Cited by 563
Cited by
The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases
Gasparyan, A. Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M., & Kitas, G. D. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.4.345 · Cited by 607
Mobbs, J. I., Black, K. A., Tran, M., Burger, W. A. C., Venugopal, H., Holman, T. R., Holinstat, M., Thal, D. M., & Glukhova, A. (2023) · Blood · doi:10.1182/blood.2023020441 · Cited by 22
Self-citationLiu, M., Zhao, W., Ma, C., Awais, M., Chen, X., Feng, Y., Wang, T., Zhou, S., Bai, Y., Jiang, S., et al. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138506 · Cited by 12
Metadata
- Authors
- Yeung, J., Li, W., & Holinstat, M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 70
- Issue
- 3
- Pages
- 526-548
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2809650874
- Cited by
- 242
- References
- 9
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. https://app.cochat.ai/papers/10.1124/pr.117.014530
- The paper
- Yeung, J., Li, W., & Holinstat, M. (2018). Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacological Reviews. https://doi.org/10.1124/pr.117.014530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.